STOCK TITAN

Global COPD and Asthma Devices Market 2022 - 2027: Players Include Adherium, Aristopharma, AstraZeneca, Baxter International and Boehringer Ingelheim International

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

DUBLIN, Feb. 3, 2023 /PRNewswire/ -- The "COPD and Asthma Devices Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to  ResearchAndMarkets.com's offering.

Research and Markets Logo

The global COPD and asthma devices market size reached US$ 40.82 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 57.09 Billion by 2027, exhibiting a CAGR of 5.75% during 2021-2027.

Companies Mentioned

  • Adherium Limited
  • Aristopharma Ltd.
  • AstraZeneca PLC
  • Baxter International Inc.
  • Boehringer Ingelheim International GmbH
  • Cohero Health Inc.
  • Koninklijke Philips N.V.
  • Omron Corporation
  • Pari Respiratory Equipment Inc.
  • Recipharm AB
  • Verona Pharma plc.

Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

Chronic obstructive pulmonary disease (COPD) is an inflammatory disease that leads to obstructed airflow from the lungs. Its early symptoms include shortness of breath, wheezing, chest tightness, chronic cough with or without mucus, frequent cold, and throat soreness.

On the other hand, asthma, also known as bronchial asthma, is a respiratory disorder that affects the airways in the lungs. Its symptoms are shortness of breath, chest tightness, trouble sleeping, and coughing or wheezing attacks.

These respiratory diseases are treated using various devices that help deliver inhaled medication. COPD and asthma devices, also known as pulmonary drug delivery devices, are used as permanent treatment or rescue therapy for respiratory diseases. As a result, they are gaining immense traction across the globe.

The growing global geriatric population, which is highly susceptible to chronic respiratory disorders, represents one of the key factors positively influencing the market. In addition, rising occurrences of respiratory diseases caused due to the rising smoking of cigarettes are increasing the sales of COPD and asthma devices.

Apart from this, the increasing expenditure on healthcare and continuous automation in the healthcare industry are contributing to the market growth. The widespread adoption of advanced medical solutions is offering lucrative growth opportunities to manufacturers across the globe.

At present, healthcare practitioners and pulmonary diseases specialists are preferring a combination of a drug and a device on account of their fast and effective outcome. Furthermore, the expansion of chemical industries is resulting in the rising environmental pollution level and breathing problems, which, in turn, is driving the market.

Additionally, the introduction of portable drug delivery devices is propelling the market growth.

Key Questions Answered in This Report:

  • How has the global COPD and asthma devices market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global COPD and asthma devices market?
  • What are the key regional markets?
  • What is the breakup of the market based on the product?
  • What is the breakup of the market based on the indication?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global COPD and asthma devices market and who are the key players?
  • What is the degree of competition in the industry?

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction
4.1 Overview
4.2 Key Industry Trends

5 Global COPD and Asthma Devices Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Product
6.1 Inhalers
6.1.1 Market Trends
6.1.2 Key Segments
6.1.2.1 Drug Powdered Inhalers (DPIs)
6.1.2.2 Metered Dose Inhalers (MDIs)
6.1.2.3 Soft Mist Inhalers
6.1.3 Market Forecast
6.2 Nebulizers
6.2.1 Market Trends
6.2.2 Key Segments
6.2.2.1 Compressor Nebulizers
6.2.2.2 Ultrasonic Nebulizers
6.2.2.3 Mesh Nebulizers
6.2.3 Market Forecast

7 Market Breakup by Indication
7.1 Asthma
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 COPD
7.2.1 Market Trends
7.2.2 Market Forecast

8 Market Breakup by Distribution Channel
8.1 Retail Pharmacies
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Hospitals
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Online Pharmacies
8.3.1 Market Trends
8.3.2 Market Forecast

9 Market Breakup by Region

10 SWOT Analysis

11 Value Chain Analysis

12 Porters Five Forces Analysis

13 Price Analysis

14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players

For more information about this report visit https://www.researchandmarkets.com/r/ffsfmm-and-asthma?w=5

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com   

For E.S.T Office Hours Call +1-917-300-0470 
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716 

Logo:  https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg



Cision View original content:https://www.prnewswire.com/news-releases/global-copd-and-asthma-devices-market-2022---2027-players-include-adherium-aristopharma-astrazeneca-baxter-international-and-boehringer-ingelheim-international-301738527.html

SOURCE Research and Markets

Verona Pharma plc

NASDAQ:VRNA

VRNA Rankings

VRNA Latest News

VRNA Stock Data

1.22B
440.24M
4.28%
85.6%
8.1%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States of America
LONDON

About VRNA

verona pharma is a clinical stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. we are currently focused on developing our novel lead therapeutic candidate in the treatment of chronic obstructive pulmonary fibrosis (copd) and cystic fibrosis (cf), and may expand our pipeline to help address the gaps in treatment of other respiratory diseases. we are led by a team with deep industry experience, including extensive backgrounds in the discovery, development and commercialization of respiratory therapies. in addition, we have established relationships with leading research institutions and advocacy organizations in the respiratory space and have received awards in support of our continued work and innovation. verona pharma is listed on the nasdaq global market in the united states under the ticker symbol vrna and on the london stock exchange in the united kin